A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Have Hb≥10 g/dL in Response to Anti-C5 Antibody and Switch to Iptacopan
收藏DataCite Commons2026-03-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012915/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study was to find out if iptacopan is effective and safe in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switched from their current standard of care treatment (eculizumab or ravulizumab) to study treatment, iptacopan/LNP023.
提供机构：
Vivli
创建时间：
2026-03-27
